Fig. 6.

Effects on myeloid regulatory factors in vivo. B16 cells were implanted on day 1. Beginning on day 10, mice were treated with decitabine (DAC), IL-2, and/or ODN1826 (DAC) for 2 weeks. A group of mice was not treated. Tumors, lymph nodes, and spleens were harvested on day 24. Mouse myeloid markers were assessed by qRT-PCR and compared to the group not treated. Data represent mean RQ, n = 4 mice per group. Mean RQ changes >0.5 log (dotted line) were considered significant. * mean RQ changes >0.5 log compared to without DAC